Search research articles
Contact Us
Filters
Showing results (71-80 of 78) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 78 results.
Cancer Immunology, Immunotherapy : CII
|
May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Matteo Santoni, Zin W Myint, Thomas Büttner, et al.
Targeted Oncology
|
October 1, 2024
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> Study
Ondřej Fiala, Francesco Massari, Umberto Basso, et al.
Clinical Genitourinary Cancer
|
April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Targeted Oncology
|
June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Minerva Urology and Nephrology
|
August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Camillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
European Urology Oncology
|
July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
Cancer Immunology, Immunotherapy : CII
|
September 7, 2023
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
Ondřej Fiala, Sebastiano Buti, Hideki Takeshita, et al.
Cancer Immunology, Immunotherapy : CII
|
April 18, 2024
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Francesco Massari, Matteo Santoni, Hideki Takeshita, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 78) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 78 results.
Cancer Immunology, Immunotherapy : CII
|
May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Matteo Santoni, Zin W Myint, Thomas Büttner, et al.
Targeted Oncology
|
October 1, 2024
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> Study
Ondřej Fiala, Francesco Massari, Umberto Basso, et al.
Clinical Genitourinary Cancer
|
April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Targeted Oncology
|
June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Minerva Urology and Nephrology
|
August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Camillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
European Urology Oncology
|
July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
Cancer Immunology, Immunotherapy : CII
|
September 7, 2023
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
Ondřej Fiala, Sebastiano Buti, Hideki Takeshita, et al.
Cancer Immunology, Immunotherapy : CII
|
April 18, 2024
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Francesco Massari, Matteo Santoni, Hideki Takeshita, et al.
Page
of 8